{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:01:45Z","timestamp":1785495705374,"version":"3.56.0"},"reference-count":45,"publisher":"Akademiai Kiado Zrt.","issue":"52","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2025,12,28]]},"abstract":"<jats:p>A szerz\u0151k egy k\u00f6zel 20 \u00e9vvel kor\u00e1bban szkizofr\u00e9ni\u00e1val diagnosztiz\u00e1lt \u00e9s gondozott\n                    p\u00e1ciens eset\u00e9t k\u00f6zlik, akin\u00e9l neurol\u00f3giai status\u00e1nak rapid v\u00e1ltoz\u00e1sa miatt\n                    diagnosztikus rev\u00edzi\u00f3 v\u00e1lt sz\u00fcks\u00e9gess\u00e9. A p\u00e1ciens t\u00e1volabbi anamn\u00e9zis\u00e9ben\n                    narcolepsia \u00e9s pikkelys\u00f6m\u00f6r is szerepelt. Legutols\u00f3, pszichotikus relapsus\n                    miatti pszichi\u00e1triai fekv\u0151beteg-oszt\u00e1lyos m\u00e1sf\u00e9l \u00e9vvel kezel\u00e9s\u00e9t k\u00f6vet\u0151en,\n                    stabil fenntart\u00f3, kombin\u00e1lt antipszichotikum-kezel\u00e9s mellett kezdetben enyhe\n                    als\u00f3 v\u00e9gtagi t\u00falmozg\u00e1sok jelentkeztek. A kivizsg\u00e1l\u00e1s kezdet\u00e9n ezeket\n                    antipszichotikum-mell\u00e9khat\u00e1snak tartottuk, majd az antipszichotikum\n                    d\u00f3ziscs\u00f6kkent\u00e9se melletti klinikai javul\u00e1s hi\u00e1nya, a t\u00falmozg\u00e1sok\n                    generaliz\u00e1l\u00f3d\u00e1sa \u00e9s a gyors progresszi\u00f3 miatt neurol\u00f3giai kivizsg\u00e1l\u00e1s indult.\n                    Ennek eredm\u00e9nyek\u00e9ppen, genetikai vizsg\u00e1lat alapj\u00e1n, Huntington-k\u00f3r igazol\u00f3dott.\n                    A beteg neuropszichol\u00f3giai status\u00e1ban a diagn\u00f3ziskor dementiaszint\u0171 hanyatl\u00e1st\n                    nem \u00e9szlelt\u00fcnk, de egyes kognit\u00edv r\u00e9szk\u00e9pess\u00e9gekben elt\u00e9r\u00e9seket m\u00e9rt\u00fcnk. Az\n                    ut\u00e1nk\u00f6vet\u00e9s sor\u00e1n kis d\u00f3zis\u00fa parci\u00e1lis dopaminreceptor-agonista \u00e9s cs\u00f6kkentett\n                    d\u00f3zis\u00fa klozapin kombin\u00e1ci\u00f3ja mellett pszichotikus relapsust nem \u00e9szlelt\u00fcnk,\n                    kognit\u00edv statusa enyh\u00e9n progredi\u00e1lt. A motoros t\u00fcnetek a Huntington-k\u00f3r\n                    progn\u00f3zis\u00e1nak megfelel\u0151en, a gy\u00f3gyszeres kezel\u00e9s ellen\u00e9re is enyhe progresszi\u00f3t\n                    mutatnak. Eset\u00fcnket a rendelkez\u00e9sre \u00e1ll\u00f3 irodalmi adatok t\u00fckr\u00e9ben, azok\n                    \u00f6sszegz\u00e9s\u00e9vel egy\u00fctt mutatjuk be. Orv Hetil. 2025; 166(52): 2064\u20132072.<\/jats:p>","DOI":"10.1556\/650.2025.33430","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T06:10:07Z","timestamp":1766902207000},"page":"2064-2072","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["A premotoros szakaszban szkizofreniform pszich\u00f3zissal \u00e9s narcolepsi\u00e1val jelentkez\u0151 Huntington-k\u00f3r esete"],"prefix":"10.1556","volume":"166","author":[{"given":"Gy\u00f6ngyi","family":"Szab\u00f3","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinika Budapest, Balassa u. 6., 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rta","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Genomikai Medicina \u00e9s Ritka Betegs\u00e9gek Int\u00e9zete Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ra","family":"B\u00e1lint","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinika Budapest, Balassa u. 6., 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Hidasi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinika Budapest, Balassa u. 6., 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria Judit","family":"Moln\u00e1r","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Genomikai Medicina \u00e9s Ritka Betegs\u00e9gek Int\u00e9zete Budapest Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"R\u00e9thelyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinika Budapest, Balassa u. 6., 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-5732","authenticated-orcid":true,"given":"L\u00e1szl\u00f3","family":"Tombor","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Pszichi\u00e1triai \u00e9s Pszichoter\u00e1pi\u00e1s Klinika Budapest, Balassa u. 6., 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Anderson KE, Marder KS. An overview of psychiatric symptoms in\n                    Huntington\u2019s disease. Curr Psychiatry Rep. 2001; 3: 379-388.\n                        https:\/\/doi.org\/10.1007\/s11920-996-0030-2","DOI":"10.1007\/s11920-996-0030-2"},{"key":"R2","unstructured":"T\u00f3th T, N\u00e9meti M, Papp Z. Pre-symptomatic diagnosis of Huntington\n                    disease by polymerase chain reaction. [Polimer\u00e1z l\u00e1ncreakci\u00f3n alapul\u00f3\n                    praesymptom\u00e1s diagn\u00f3zis Huntington-betegs\u00e9gben.] Orv Hetil. 1996; 137: 451-454.\n                    [Hungarian]"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Xuereb JH, MacMillan JC, Snell R, et al. Neuropathological diagnosis\n                    and CAG repeat expansion in Huntington\u2019s disease. J Neurol Neurosurg Psychiatry\n                    1996; 60: 78-81.\n                    https:\/\/doi.org\/10.1136\/jnnp.60.1.78","DOI":"10.1136\/jnnp.60.1.78"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Paoli RA, Botturi A, Ciammola A, et al. Neuropsychiatric burden in\n                    Huntington\u2019s disease. Brain Sci. 2017; 7: 67.\n                        https:\/\/doi.org\/10.3390\/brainsci7060067","DOI":"10.3390\/brainsci7060067"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Houge G, Bruland O, Bj\u00f8rnevoll I, et al. De novo Huntington disease\n                    caused by 26-44 CAG repeat expansion on a low-risk haplotype. Neurology 2013;\n                    81: 1099-1100.\n                    https:\/\/doi.org\/10.1212\/WNL.0b013e3182a4a4af","DOI":"10.1212\/WNL.0b013e3182a4a4af"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Findlay I, Nagy B, et al. Accurate sizing of (CAG)n repeats\n                    causing Huntington disease by fluorescent PCR. Clin Chem. 1997; 43: 2422-2423.\n                        https:\/\/doi.org\/10.1093\/clinchem\/43.12.2422","DOI":"10.1093\/clinchem\/43.12.2422"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"T\u00f3th T, Nagy B, Papp Z. PCR reagents for detection of (CAG)n repeats\n                    in Huntington disease. Clin Chem. 1997; 43: 1463. Erratum: Clin Chem 1997; 43:\n                    2004. https:\/\/doi.org\/10.1093\/clinchem\/43.8.1463","DOI":"10.1093\/clinchem\/43.8.1463"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Reilmann R, Feigin A, Rosser AE, et al. Pridopidine in early-stage\n                    manifest Huntington\u2019s disease: a phase 3 trial. Nat Med. 2025. doi:\n                    10.1038\/s41591-025-03920-3.\n                        https:\/\/doi.org\/10.1038\/s41591-025-03920-3","DOI":"10.1038\/s41591-025-03920-3"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Csontos K, Ernyei B, V\u00e9rtes E, et al. Severe choreiform movement\n                    disorder following COVID-19. [S\u00falyos choreiform mozg\u00e1szavar COVID-19-betegs\u00e9get\n                    k\u00f6vet\u0151en.] Orv Hetil. 2024; 165: 1130-1134. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33084","DOI":"10.1556\/650.2024.33084"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Lovig C, Herold R, P\u00e1l E, et al. Case report and literature review\n                    of AIDS-related progressive multifocal leukoencephalopathy diagnosed in a\n                    psychiatric department. [Pszichi\u00e1triai oszt\u00e1lyon diagnosztiz\u00e1lt, AIDS talaj\u00e1n\n                    kialakult progressz\u00edv multifok\u00e1lis leukoencephalopathia.] Orv Hetil. 2024; 165:\n                    1295-1302. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2024.33102","DOI":"10.1556\/650.2024.33102"},{"key":"R11","unstructured":"Gupta V, Deswal RS. Huntington\u2019s disease presenting with\n                    schizophrenic symptoms: a case report. Indian J Psychiatry 1992; 34:\n                    59-61."},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Lovestone S, Hodgson S, Sham P, et al. Familial psychiatric\n                    presentation of Huntington\u2019s disease. J Med Genet. 1996; 33: 128-131.\n                        https:\/\/doi.org\/10.1136\/jmg.33.2.128","DOI":"10.1136\/jmg.33.2.128"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Tost H, Wendt CS, Schmitt A, et al. Huntington\u2019s disease:\n                    phenomenological diversity of a neuropsychiatric condition that challenges\n                    traditional concepts in neurology and psychiatry. Am J Psychiatry 2004; 161:\n                    28-34. https:\/\/doi.org\/10.1176\/appi.ajp.161.1.28","DOI":"10.1176\/appi.ajp.161.1.28"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Corr\u00eaa BB, Xavier M, Guimar\u00e3es J. Association of Huntington\u2019s\n                    disease and schizophrenia-like psychosis in a Huntington\u2019s disease pedigree.\n                    Clin Pract Epidemiol Ment Health 2006; 2: 1.\n                        https:\/\/doi.org\/10.1186\/1745-0179-2-1","DOI":"10.1186\/1745-0179-2-1"},{"key":"R15","unstructured":"Radanovi\u0107-Grguric\u0107 L, Petek A, Laufer D, et al. Pharmacologic side\n                    effects and\/or neurologic disorder: case report. Psychiatr Danub. 2009; 21:\n                    575-578."},{"key":"R16","doi-asserted-by":"crossref","unstructured":"kano T, Ono S, Yamaguchi J, et al. Modified electroconvulsive\n                    therapy for the treatment of refractory schizophrenia-like psychosis associated\n                    with Huntington\u2019s disease. J Neurol. 2013; 260: 312-314.\n                        https:\/\/doi.org\/10.1007\/s00415-012-6720-2","DOI":"10.1007\/s00415-012-6720-2"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Gama Marques J, Carnot MJ. Huntington\u2019s disease in a patient with\n                    15-year history of Capgras delusion misdiagnosed as paranoid schizophrenia. Gen\n                    Hosp Psychiatry 2016; 39: 97-98.\n                        https:\/\/doi.org\/10.1016\/j.genhosppsych.2015.11.007","DOI":"10.1016\/j.genhosppsych.2015.11.007"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Lv C, Zhang Z, Zhang Y, et al. A rare case report of Huntington\u2019s\n                    disease with severe psychiatric symptoms as initial manifestations. Psychiatr\n                    Genet. 2024; 34: 15-18.\n                    https:\/\/doi.org\/10.1097\/YPG.0000000000000359","DOI":"10.1097\/YPG.0000000000000359"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Xu C, Yogaratnam J, Tan N, et al. Psychosis, treatment emergent\n                    extrapyramidal events, and subsequent onset of Huntington\u2019s disease: a case\n                    report and review of the literature. Clin Psychopharmacol Neurosci. 2016; 14:\n                    302-304. https:\/\/doi.org\/10.9758\/cpn.2016.14.3.302","DOI":"10.9758\/cpn.2016.14.3.302"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Calabrese F, Tarazi FI, Racagni G, et al. The role of dopamine D3\n                    receptors in the mechanism of action of cariprazine. CNS Spectr. 2020; 25:\n                    343-351. https:\/\/doi.org\/10.1017\/S109285291900083X","DOI":"10.1017\/S109285291900083X"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"N\u00e9meth G, Laszlovszky I, Czobor P, et al. Cariprazine versus\n                    risperidone monotherapy for treatment of predominant negative symptoms in\n                    patients with schizophrenia: a randomised, double-blind, controlled trial.\n                    Lancet 2017; 389: 1103-1113. Erratum: Lancet 2017; 389: 1102.\n                        https:\/\/doi.org\/10.1016\/S0140-6736(17)30060-0","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Sachs GS, Yeung PP, Rekeda L, et al. Adjunctive cariprazine for the\n                    treatment of patients with major depressive disorder: a randomized,\n                    double-blind, placebo-controlled phase 3 study. Am J Psychiatry 2023; 180:\n                    241-251. https:\/\/doi.org\/10.1176\/appi.ajp.20220504","DOI":"10.1176\/appi.ajp.20220504"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Csehi R, Moln\u00e1r V, Fedor M, et al. The improvement of motor symptoms\n                    in Huntington\u2019s disease during cariprazine treatment. Orphanet J Rare Dis. 2023;\n                    18: 375. https:\/\/doi.org\/10.1186\/s13023-023-02930-z","DOI":"10.1186\/s13023-023-02930-z"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Moln\u00e1r MJ, Moln\u00e1r V, Fedor M, et al. Improving mood and cognitive\n                    symptoms in Huntington\u2019s disease with cariprazine treatment. Front Psychiatry\n                    2022; 12: 825532.\n                    https:\/\/doi.org\/10.3389\/fpsyt.2021.825532","DOI":"10.3389\/fpsyt.2021.825532"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"An der Heiden W, H\u00e4fner H. The epidemiology of onset and course of\n                    schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2000; 250: 292-303.\n                        https:\/\/doi.org\/10.1007\/s004060070004","DOI":"10.1007\/s004060070004"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"R\u00f3ka ES, B\u00e1lint S, Tombor L. A case of Turner syndrome associated\n                    with schizophrenia. [Szkizofr\u00e9ni\u00e1val t\u00e1rsul\u00f3 Turner-szindr\u00f3ma.] Orv Hetil. 2023;\n                    164: 753-757. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2023.32764","DOI":"10.1556\/650.2023.32764"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Moln\u00e1r MJ, Cs S\u00e1gi J, Szab\u00f3 L, et al. The transition of children\n                    with rare diseases from pediatric to adult care. [A ritka betegs\u00e9gben szenved\u0151\n                    gyermekek \u00e1tvezet\u00e9se a feln\u0151ttell\u00e1t\u00e1sba.] Orv Hetil. 2022; 163: 2021-2026.\n                    [Hungarian] https:\/\/doi.org\/10.1556\/650.2022.32660","DOI":"10.1556\/650.2022.32660"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Cavallo M, Sergi A, Pagani M. Cognitive and social cognition\n                    deficits in Huntington\u2019s disease differ between the prodromal and the manifest\n                    stages of the condition: a scoping review of recent evidence. Br J Clin Psychol.\n                    2022; 61: 214-241. https:\/\/doi.org\/10.1111\/bjc.12337","DOI":"10.1111\/bjc.12337"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Tsuang D, DiGiacomo L, Lipe H, et al. Familial aggregation of\n                    schizophrenia-like symptoms in Huntington\u2019s disease. Am J Med Genet. 1998; 81:\n                    323-327.\n                        https:\/\/doi.org\/10.1002\/(SICI)1096-8628(19980710)81:4<323::AID-AJMG9>3.0.CO2-U;","DOI":"10.1002\/(SICI)1096-8628(19980710)81:4<323::AID-AJMG9>3.3.CO;2-M"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Ellis N, Tee A, McAllister B, et al. Genetic risk underlying\n                    psychiatric and cognitive symptoms in Huntington\u2019s disease. Biol Psychiatry\n                    2020; 87: 857-865.\n                    https:\/\/doi.org\/10.1016\/j.biopsych.2019.12.010","DOI":"10.1016\/j.biopsych.2019.12.010"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Tsuang DW, Greenwood TA, Jayadev S, et al. A genetic study of\n                    psychosis in Huntington\u2019s disease: evidence for the involvement of glutamate\n                    signaling pathways. J Huntingtons Dis. 2018; 7: 51-59.\n                        https:\/\/doi.org\/10.3233\/JHD-170277","DOI":"10.3233\/JHD-170277"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Snyder SH. The dopamine hypothesis of schizophrenia: focus on the\n                    dopamine receptor. Am J Psychiatry 1976; 133: 197-202.\n                        https:\/\/doi.org\/10.1176\/ajp.133.2.197","DOI":"10.1176\/ajp.133.2.197"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review\n                    and reconceptualization. Am J Psychiatry 1991; 148: 1474-1486.\n                        https:\/\/doi.org\/10.1176\/ajp.148.11.1474","DOI":"10.1176\/ajp.148.11.1474"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Koch ET, Raymond LA. Dysfunctional striatal dopamine signaling in\n                    Huntington\u2019s disease. J Neurosci Res. 2019; 97: 1636-1654.\n                        https:\/\/doi.org\/10.1002\/jnr.24495","DOI":"10.1002\/jnr.24495"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Chen JY, Wang EA, Cepeda C, et al. Dopamine imbalance in\n                    Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility. Front\n                    Neurosci. 2013; 7: 114.\n                    https:\/\/doi.org\/10.3389\/fnins.2013.00114","DOI":"10.3389\/fnins.2013.00114"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Kiss B, Laszlovszky I, Kr\u00e1mos B, et al. Neuronal dopamine D3\n                    receptors: translational implications for preclinical research and CNS\n                    disorders. Biomolecules 2021; 11: 104.\n                        https:\/\/doi.org\/10.3390\/biom11010104","DOI":"10.3390\/biom11010104"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Herzog-Krzywoszanska R, Krzywoszanski L. Sleep disorders in\n                    Huntington\u2019s disease. Front Psychiatry 2019; 10: 221.\n                        https:\/\/doi.org\/10.3389\/fpsyt.2019.00221","DOI":"10.3389\/fpsyt.2019.00221"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Arnulf I, Nielsen J, Lohmann E, et al. Rapid eye movement sleep\n                    disturbances in Huntington disease. Arch Neurol. 2008; 65: 482-488. Erratum:\n                    Arch Neurol. 2008; 65: 1478.\n                        https:\/\/doi.org\/10.1001\/archneur.65.4.482","DOI":"10.1001\/archneur.65.4.482"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Peters\u00e9n A, Gil J, Maat-Schieman ML, et al. Orexin loss in\n                    Huntington\u2019s disease. Hum Mol Genet. 2005; 14: 39-47.\n                        https:\/\/doi.org\/10.1093\/hmg\/ddi004","DOI":"10.1093\/hmg\/ddi004"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Shan L, Fronczek R, Lammers GJ, et al. The tuberomamillary nucleus\n                    in neuropsychiatric disorders. Handb Clin Neurol. 2021; 180: 389-400.\n                        https:\/\/doi.org\/10.1016\/B978-0-12-820107-7.00024-0","DOI":"10.1016\/B978-0-12-820107-7.00024-0"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus\n                    placebo or modafinil in patients with narcolepsy: a double-blind, randomised\n                    trial. Lancet Neurol. 2013; 12: 1068-1075.\n                        https:\/\/doi.org\/10.1016\/S1474-4422(13)70225-4","DOI":"10.1016\/S1474-4422(13)70225-4"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of\n                    pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind,\n                    placebo-controlled trial. Lancet Neurol. 2017; 16: 200-207.\n                        https:\/\/doi.org\/10.1016\/S1474-4422(16)30333-7","DOI":"10.1016\/S1474-4422(16)30333-7"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Haig GM, Bain E, Robieson W, et al. A randomized trial of the\n                    efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment\n                    associated with schizophrenia. Schizophr Bull. 2014; 40: 1433-1442.\n                        https:\/\/doi.org\/10.1093\/schbul\/sbt240","DOI":"10.1093\/schbul\/sbt240"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Jarskog LF, Lowy MT, Grove RA, et al. A Phase II study of a\n                    histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable\n                    schizophrenia subjects on antipsychotic therapy. Schizophr Res. 2015; 164:\n                    136-142.\n                    https:\/\/doi.org\/10.1016\/j.schres.2015.01.041","DOI":"10.1016\/j.schres.2015.01.041"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Kishi T, Iwata N. Efficacy and tolerability of histamine-2 receptor\n                    antagonist adjunction of antipsychotic treatment in schizophrenia: a\n                    meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry 2015;\n                    48: 30-36. https:\/\/doi.org\/10.1055\/s-0034-1390478","DOI":"10.1055\/s-0034-1390478"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/52\/article-p2064.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/52\/article-p2064.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/166\/52\/article-p2064.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T10:51:04Z","timestamp":1785495064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/166\/52\/article-p2064.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":45,"journal-issue":{"issue":"52"},"URL":"https:\/\/doi.org\/10.1556\/650.2025.33430","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}